miR-199a Downregulation as a Driver of the NOX4/HIF-1α/VEGF-A Pathway in Thyroid and Orbital Adipose Tissues from Graves' Patients.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
23 Dec 2021
Historique:
received: 02 11 2021
revised: 14 12 2021
accepted: 22 12 2021
entrez: 11 1 2022
pubmed: 12 1 2022
medline: 2 2 2022
Statut: epublish

Résumé

Graves' disease (GD) is an autoimmune thyroiditis often associated with Graves' orbitopathy (GO). GD thyroid and GO orbital fat share high oxidative stress (OS) and hypervascularization. We investigated the metabolic pathways leading to OS and angiogenesis, aiming to further decipher the link between local and systemic GD manifestations. Plasma and thyroid samples were obtained from patients operated on for multinodular goiters (controls) or GD. Orbital fats were from GO or control patients. The NADPH-oxidase-4 (NOX4)/HIF-1α/VEGF-A signaling pathway was investigated by Western blotting and immunostaining. miR-199a family expression was evaluated following quantitative real-time PCR and/or in situ hybridization. In GD thyroids and GO orbital fats, NOX4 was upregulated and correlated with HIF-1α stabilization and VEGF-A overexpression. The biotin assay identified NOX4, HIF-1α and VEGF-A as direct targets of miR-199a-5p in cultured thyrocytes. Interestingly, GD thyroids, GD plasmas and GO orbital fats showed a downregulation of miR-199a-3p/-5p. Our results also highlighted an activation of STAT-3 signaling in GD thyroids and GO orbital fats, a transcription factor known to negatively regulate miR-199a expression. We identified NOX4/HIF-1α/VEGF-A as critical actors in GD and GO. STAT-3-dependent regulation of miR-199a is proposed as a common driver leading to these events in GD thyroids and GO orbital fats.

Identifiants

pubmed: 35008579
pii: ijms23010153
doi: 10.3390/ijms23010153
pmc: PMC8745087
pii:
doi:

Substances chimiques

HIF1A protein, human 0
Hypoxia-Inducible Factor 1, alpha Subunit 0
MicroRNAs 0
VEGFA protein, human 0
Vascular Endothelial Growth Factor A 0
mirn199 microRNA, human 0
NADPH Oxidase 4 EC 1.6.3.-
NOX4 protein, human EC 1.6.3.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Int J Mol Sci. 2021 Apr 07;22(8):
pubmed: 33916948
Oncogene. 2012 Mar 1;31(9):1117-29
pubmed: 21841825
Endocrinology. 2008 Jan;149(1):424-33
pubmed: 17884933
Antioxidants (Basel). 2019 May 10;8(5):
pubmed: 31083324
PLoS Genet. 2013;9(2):e1003291
pubmed: 23459460
Eur Thyroid J. 2020 Dec;9(Suppl 1):40-50
pubmed: 33511084
Antioxid Redox Signal. 2019 Oct 1;31(10):687-709
pubmed: 31250671
Cancer Res. 2003 Jun 1;63(11):2864-71
pubmed: 12782592
Eur Thyroid J. 2013 Sep;2(3):160-7
pubmed: 24847449
Med Sci Monit. 2016 Apr 11;22:1210-7
pubmed: 27062921
Oncotarget. 2014 May 15;5(9):2513-28
pubmed: 24810336
Biochim Biophys Acta. 2007 Jul;1773(7):1015-27
pubmed: 17553579
Thyroid. 2005 Mar;15(3):205-9
pubmed: 15785239
Eur Thyroid J. 2012 Jul;1(2):80-7
pubmed: 24783001
Neuro Endocrinol Lett. 2003 Oct;24(5):293-303
pubmed: 14647000
FASEB J. 2005 Aug;19(10):1296-8
pubmed: 15919761
Endocr Rev. 2013 Apr;34(2):209-38
pubmed: 23349248
Mol Biol Cell. 2010 Jun 15;21(12):2087-96
pubmed: 20427574
Cell Physiol Biochem. 2015;35(5):1934-42
pubmed: 25871842
Indian J Ophthalmol. 2012 Mar-Apr;60(2):87-93
pubmed: 22446901
Arterioscler Thromb Vasc Biol. 2009 Feb;29(2):239-45
pubmed: 19057021
J Clin Endocrinol Metab. 2016 Dec;101(12):4834-4842
pubmed: 27610652
Front Immunol. 2017 Apr 07;8:396
pubmed: 28439272
Endocr Relat Cancer. 2010 Jan 29;17(1):27-37
pubmed: 19779036
Nat Rev Endocrinol. 2016 Aug;12(8):485-94
pubmed: 27174022
Mol Cell Endocrinol. 2021 Aug 20;534:111363
pubmed: 34116129
Exp Cell Res. 2002 Feb 15;273(2):187-96
pubmed: 11822874
J Clin Endocrinol Metab. 2014 May;99(5):1722-32
pubmed: 24476075
J Clin Endocrinol Metab. 1998 Nov;83(11):3908-12
pubmed: 9814467
J Cell Sci. 2012 Feb 15;125(Pt 4):956-64
pubmed: 22399808
Endocrine. 2017 Jul;57(1):125-137
pubmed: 28547036
J Pathol. 2014 Feb;232(3):330-43
pubmed: 24155090
Front Cell Dev Biol. 2020 Dec 07;8:594528
pubmed: 33365310
Arterioscler Thromb Vasc Biol. 2007 Apr;27(4):755-61
pubmed: 17272744
Thyroid. 2015 Sep;25(9):1033-42
pubmed: 26176182
Mol Biol Cell. 2010 Sep 15;21(18):3247-57
pubmed: 20660157
J Cancer. 2017 Mar 12;8(6):940-949
pubmed: 28529605
Horm Metab Res. 2017 Mar;49(3):180-184
pubmed: 28192819
Mol Cell Endocrinol. 2018 Nov 15;476:155-164
pubmed: 29753771
Thyroid. 2021 Apr;31(4):627-637
pubmed: 32977740
Int J Mol Sci. 2014 May 14;15(5):8526-38
pubmed: 24830555
Endocr Relat Cancer. 2019 Mar 1;26(3):R131-R143
pubmed: 30615595
J Biol Chem. 2000 Jul 28;275(30):23227-33
pubmed: 10806195
Oncotarget. 2016 Feb 16;7(7):7683-700
pubmed: 26655502
Endocrinology. 2015 Feb;156(2):707-20
pubmed: 25406019
J Biol Chem. 1999 Dec 24;274(52):37265-9
pubmed: 10601291
Front Immunol. 2017 May 09;8:521
pubmed: 28536577
J Physiol Biochem. 2019 Feb;75(1):73-81
pubmed: 30426460
IUBMB Life. 2001 Feb;51(2):105-9
pubmed: 11463161
Arterioscler Thromb Vasc Biol. 2018 Oct;38(10):2345-2357
pubmed: 29976767
Am J Physiol Endocrinol Metab. 2009 Jun;296(6):E1414-22
pubmed: 19336661
Eur Heart J. 2011 May;32(10):1287-97
pubmed: 20965886
J Mol Endocrinol. 2021 Feb;66(2):R33-R55
pubmed: 33295879
Ophthalmology. 2016 Sep;123(9):2028-36
pubmed: 27423310
Clin Ophthalmol. 2015 Dec 03;9:2271-6
pubmed: 26664042
Clin Endocrinol (Oxf). 2003 Sep;59(3):321-7
pubmed: 12919155
J Clin Endocrinol Metab. 2018 Oct 1;103(10):3668-3677
pubmed: 30099546
Circ Res. 2009 Apr 10;104(7):879-86
pubmed: 19265035
Front Cell Dev Biol. 2021 Feb 18;8:620615
pubmed: 33681184
Appl Immunohistochem Mol Morphol. 2006 Jun;14(2):203-7
pubmed: 16785791
Br J Biomed Sci. 2017 Apr;74(2):90-94
pubmed: 28367740
Cell Physiol Biochem. 2015;37(4):1289-300
pubmed: 26430741

Auteurs

Julie Craps (J)

Pole of Pharmacology and Therapeutics, Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain (UCLouvain), B-1200 Brussels, Belgium.
Pole of Morphology, Institute of Experimental and Clinical Research (IREC), UCLouvain, B-1200 Brussels, Belgium.

Virginie Joris (V)

Pole of Pharmacology and Therapeutics, Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain (UCLouvain), B-1200 Brussels, Belgium.

Lelio Baldeschi (L)

Department of Ophthalmology, Cliniques Universitaires Saint Luc, UCLouvain, B-1200 Brussels, Belgium.

Chantal Daumerie (C)

Departement of Endocrinology, Cliniques Universitaires Saint Luc, UCLouvain, B-1200 Brussels, Belgium.

Alessandra Camboni (A)

Departement of Anatomopathology, Cliniques Universitaires Saint Luc, UCLouvain, B-1200 Brussels, Belgium.

Antoine Buemi (A)

Departement of Surgery and Abdominal Transplantation, Cliniques Universitaires Saint Luc, UCLouvain, B-1200 Brussels, Belgium.

Benoit Lengelé (B)

Pole of Morphology, Institute of Experimental and Clinical Research (IREC), UCLouvain, B-1200 Brussels, Belgium.
Department of Plastic and Reconstructive Surgery, Cliniques Universitaires Saint-Luc, UCLouvain, B-1200 Brussels, Belgium.

Catherine Behets (C)

Pole of Morphology, Institute of Experimental and Clinical Research (IREC), UCLouvain, B-1200 Brussels, Belgium.

Antonella Boschi (A)

Department of Ophthalmology, Cliniques Universitaires Saint Luc, UCLouvain, B-1200 Brussels, Belgium.

Michel Mourad (M)

Departement of Surgery and Abdominal Transplantation, Cliniques Universitaires Saint Luc, UCLouvain, B-1200 Brussels, Belgium.

Marie-Christine Many (MC)

Pole of Morphology, Institute of Experimental and Clinical Research (IREC), UCLouvain, B-1200 Brussels, Belgium.

Chantal Dessy (C)

Pole of Pharmacology and Therapeutics, Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain (UCLouvain), B-1200 Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH